Twist Bioscience launches humanized transgenic mouse model

SOUTH SAN FRANCISCO - Twist Bioscience Corporation (NASDAQ:TWST), a $2.08 billion synthetic DNA technology company with strong financial health according to InvestingPro metrics, announced the launch of a humanized transgenic (HuTg) mouse model to expand its antibody discovery services offering, according to a company press release.

The new HuTg mouse model can be paired with Twist’s existing DiversimAb mouse model and B cell screening platforms. Unlike typical HuTg models that require licensing from providers, Twist is offering this as a fee-for-service approach. The company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 4.51, positioning it well for continued innovation.

"The humanized transgenic mouse model complements our current in vivo antibody discovery platforms," said Emily M. Leproust, CEO and co-founder of Twist Bioscience, noting that the approach eliminates "often time-consuming licensing negotiations."

According to the company, the HuTg mouse model generates human antibody repertoires to accelerate lead discovery and optimization, potentially allowing customers to identify fully human hits in weeks instead of months.

Twist Bioscience provides synthetic DNA tools for customers in fields including medicine, agriculture, industrial chemicals, and defense. The company states that its silicon-based DNA Synthesis Platform provides precision at scale that would otherwise be unavailable to customers.

The announcement comes as part of Twist’s efforts to expand its antibody discovery capabilities and provide researchers with multiple methods that can be used independently or together across various disease areas. The company has demonstrated strong revenue growth of 25.3% over the last twelve months. For detailed analysis and additional insights about Twist Bioscience’s growth trajectory and financial outlook, visit InvestingPro, where you’ll find exclusive research reports and advanced financial metrics.

In other recent news, Twist Bioscience Corporation reported a record revenue of $92.8 million for the second quarter of fiscal year 2025, marking a 23% year-over-year increase. Despite this revenue growth, the company posted an earnings per share of -$0.66, missing the forecasted -$0.61. Barclays reaffirmed its Overweight rating on Twist Bioscience with a price target of $45, citing the planned spin-off of the DNA Storage division as a strategic move to reduce cash burn and achieve EBITDA break-even by the end of fiscal year 2026. Similarly, Leerink Partners maintained a Market Perform rating with a $40 price target, noting the company’s market share gains from China-based competitors but expressing concerns about long-term growth sustainability.

Evercore ISI adjusted its price target for Twist Bioscience to $50, maintaining an Outperform rating, following a review of the company’s second-quarter performance. The revenue increase was driven by a 21% rise in Synthetic Biology and a 25% increase in Next Generation Sequencing revenues. Additionally, Twist Bioscience’s gross margins exceeded expectations, despite higher stock-based compensation expenses. TD Cowen reaffirmed a Buy rating with a $58 price target, emphasizing the company’s strong positioning and resilience to industry challenges, particularly its low exposure to tariffs and NIH funding fluctuations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.